These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Glycopeptides in the treatment of staphylococcal infections.
    Author: Daschner FD, Kropec A.
    Journal: Eur J Clin Microbiol Infect Dis; 1995; 14 Suppl 1():S12-7. PubMed ID: 7729466.
    Abstract:
    Gram-positive bacteria are rapidly becoming the most important pathogens in nosocomial infections. In recent years, attention and concern have been focused on the gram-positive bacteria, Staphylococcus aureus, Staphylococcus epidermidis and Enterococcus faecalis. These microorganisms are well equipped to exert their pathogenic effects and to display virulence. Treatment of severe infections caused by gram-positive bacteria remains difficult because of the increase in infections caused by methicillin-resistant staphylococci, and this has renewed interest in the glycopeptide antibiotics, vancomycin and teicoplanin. According to National Nosocomial Infection Surveillance Study data, in 1989, 60% of coagulase-negative staphylococci and 22% of Staphylococcus aureus strains showed methicillin resistance. Among other factors, successful antimicrobial therapy depends on rapid and reliable antibiotic delivery to the infection site at a concentration adequate to inhibit the majority of infecting organisms. Glycopeptides may be important in the therapy of catheter-related infections, which are mainly caused by coagulase-negative staphylococci and Staphylococcus aureus.
    [Abstract] [Full Text] [Related] [New Search]